PRLD Prelude Therapeutics Incorporated - Common Stock
$4,33
Prix · Mai 20, 2026
Données fondamentales au Mai 12, 2026
Fourchette 52 semaines
$1–$6
75% of range
Note des analystes
BUY
9 analysts
Objectif de cours
$7
+59% upside
P/E (TTM)
-2.2
ROE
-137.7%
Marge nette
-819.6%
PRLD Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$4.33
Capitalisation Boursière
—
P/E (TTM)
-2.2
BPA (TTM)
$-1.29
Revenus (TTM)
$12M
Rendement div.
—
ROE
-137.7%
Dette/Capitaux propres
—
Fourchette 52 semaines
$1 – $6
PRLD Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$12M
2024-12-31
→
2025-12-31
BPA
$-1.29
2021-12-31
→
2025-12-31
Flux de trésorerie libre
$-56M
2020-12-31
→
2025-12-31
Marges
-819.6%
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
PRLD
Médiane des pairs
P/E (TTM)
-2.2
9.4
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
PRLD
Médiane des pairs
Operating Margin (Marge d'exploitation)
-861.3%
—
Net Profit Margin (Marge nette)
-819.6%
-205.9%
ROA
-62.8%
-30.4%
ROE
-137.7%
-54.4%
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
PRLD
Médiane des pairs
Current Ratio (Ratio de liquidité)
2.0
3.8
Quick Ratio (Ratio de liquidité réduite)
1.9
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
PRLD
Médiane des pairs
Revenue YoY (Chiffre d'affaires YoY)
73.4%
—
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
PRLD
Médiane des pairs
PRLD Consensus des analystes Opinions des analystes haussières et baissières, objectif de cours à 12 mois, potentiel de hausse
ACHAT
9 analystes
- Achat fort 3 33,3%
- Achat 5 55,6%
- Conserver 1 11,1%
- Vente 0 0,0%
- Vente forte 0 0,0%
Objectif de cours à 12 mois
4 analystes · 2026-05-14
Médiane
$7.00
← En dessous de tous les objectifs
$4.33
Bas
$4.50
Haut
$9.00
Objectif médian
$7.00
+61,7%
Objectif moyen
$6.88
+58,8%
Historique des bénéfices BPA réel vs estimation, surprise %, taux de succès, prochaine date de publication des résultats
Surprise Moyenne
0.03%
| Période | EPS Actual | BPA est. | Surprise |
|---|---|---|---|
| 31 mars 2026 | $-0.13 | $-0.25 | 0.12% |
| 31 décembre 2025 | $-0.20 | $-0.03 | -0.17% |
| 30 septembre 2025 | $-0.26 | $-0.37 | 0.11% |
| 30 juin 2025 | $-0.41 | $-0.45 | 0.04% |
| 31 mars 2025 | $-0.42 | $-0.48 | 0.06% |
Comparaison avec les pairs Indicateurs clés par rapport aux pairs du secteur
| Ticker | Capitalisation Boursière | P/E | Revenus Année/Année | Marge Nette | ROE | Marge Brute |
|---|---|---|---|---|---|---|
| PRLD | — | -2.2 | 73.4% | -819.6% | -137.7% | — |
| ELDN | $114M | -2.9 | — | — | -69.4% | — |
| RGNX | $733M | -3.8 | 104.5% | -113.8% | -122.5% | — |
| NVCT | $194M | -5.7 | — | — | -149.9% | — |
| SABS | — | — | — | — | — | — |
| MGNX | $102M | -1.4 | -0.31% | -49.9% | -87.0% | — |
| ALXO | $61M | -0.6 | — | — | -225.0% | — |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | — |
| TARA | $286M | -4.0 | — | — | -33.7% | — |
| ZNTL | $93M | -0.7 | — | — | -49.5% | — |
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 13
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Revenue | $12M | $7M | |
| R&D Expense | $94M | $118M | |
| SG&A Expense | $22M | $29M | |
| Operating Expenses | $117M | $147M | |
| Operating Income | $-105M | $-140M | |
| Other Non-op | $5M | $13M | |
| Income Tax | $0 | $0 | |
| Net Income | $-99M | $-127M | |
| EPS (Basic) | $-1.29 | $-1.68 | |
| EPS (Diluted) | $-1.29 | $-1.68 | |
| Shares (Basic) | 76,956,194 | 75,805,840 | |
| Shares (Diluted) | 76,956,194 | 75,805,840 | |
| EBITDA | $-103M | $-138M |
Bilan 18
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $35M | $12M | |
| Short-term Investments | $68M | $121M | |
| Prepaid Expense | $2M | $2M | |
| Current Assets | $106M | $136M | |
| PP&E (Net) | $5M | $7M | |
| PP&E (Gross) | $12M | $12M | |
| Accum. Depreciation | $7M | $5M | |
| Total Assets | $141M | $176M | |
| Accounts Payable | $4M | $8M | |
| Accrued Liabilities | $13M | $15M | |
| Current Liabilities | $53M | $26M | |
| Capital Leases | $15M | $15M | |
| Other Non-current Liabilities | $3M | $3M | |
| Total Liabilities | $73M | $44M | |
| Retained Earnings | $-683M | $-584M | |
| AOCI | $8.0K | $35.0K | |
| Stockholders' Equity | $69M | $131M | |
| Liabilities + Equity | $141M | $176M |
Flux de trésorerie 11
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| D&A | $2M | $2M | |
| Stock-based Comp | $12M | $21M | |
| Restructuring | $1M | · | |
| Other Non-cash | $30M | $1M | |
| Operating Cash Flow | $-56M | $-103M | |
| CapEx | $67.0K | $764.0K | |
| Investing Cash Flow | $53M | $90M | |
| Financing Cash Flow | $25M | $-120.0K | |
| Net Change in Cash | $22M | $-13M | |
| Taxes Paid | $0 | $0 | |
| Free Cash Flow | $-56M | $-104M |
Rentabilité 5
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -861.3% | -1995.9% | |
| Net Margin | -819.6% | -1816.8% | |
| EBITDA Margin | -847.2% | -1970.6% | |
| ROA | -62.8% | -56.1% | |
| ROE | -137.7% | -88.3% |
Liquidité et Solvabilité 2
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 2.0 | 5.3 | |
| Quick Ratio | 1.9 | 5.2 |
Efficacité 1
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 |
Taux de croissance 1
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Revenue YoY | 73.4% | · |
Valorisation (TTM) 4
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $12M | $7M | |
| Net Income TTM | $-99M | $-127M | |
| P/E | -2.2 | -0.8 | |
| Earnings Yield | -44.5% | -131.8% |
Compte de résultat 12
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $6M | $6M | · | $0 | $4M | $3M | |
| R&D Expense | $14M | $18M | $22M | $26M | $29M | $32M | $29M | |
| SG&A Expense | $5M | $5M | $5M | $6M | $6M | $6M | $8M | |
| Operating Expenses | $19M | $23M | $27M | $32M | $35M | $38M | $37M | |
| Operating Income | $-14M | $-17M | $-20M | $-32M | $-35M | $-34M | $-34M | |
| Other Non-op | $4M | $891.0K | $693.0K | $963.0K | $3M | $5M | $2M | |
| Net Income | $-10M | $-16M | $-20M | $-31M | $-32M | $-29M | $-32M | |
| EPS (Basic) | $-0.13 | $-0.20 | $-0.26 | $-0.41 | $-0.42 | $-0.37 | $-0.43 | |
| EPS (Diluted) | $-0.13 | $-0.20 | $-0.26 | $-0.41 | $-0.42 | $-0.37 | $-0.43 | |
| Shares (Basic) | 82,519,981 | -151,156,365 | 76,132,337 | 75,993,941 | 75,986,281 | -151,548,215 | 75,855,949 | |
| Shares (Diluted) | 82,519,981 | -151,156,365 | 76,132,337 | 75,993,941 | 75,986,281 | -151,548,215 | 75,855,949 | |
| EBITDA | $-14M | · | $-20M | $-32M | $-34M | · | $-34M |
Bilan 18
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22M | $35M | $48M | $26M | $40M | $12M | $11M | |
| Short-term Investments | $60M | $68M | $7M | $47M | $59M | $121M | $142M | |
| Prepaid Expense | $3M | $2M | $3M | $4M | $3M | $2M | $3M | |
| Current Assets | $85M | $106M | $58M | $77M | $102M | $136M | $156M | |
| PP&E (Net) | $5M | $5M | $6M | $6M | $6M | $7M | $7M | |
| PP&E (Gross) | · | $12M | · | · | · | $12M | · | |
| Accum. Depreciation | · | $7M | · | · | · | $5M | · | |
| Total Assets | $120M | $141M | $95M | $115M | $141M | $176M | $197M | |
| Accounts Payable | $2M | $4M | $3M | $5M | $6M | $8M | $6M | |
| Accrued Liabilities | $6M | $13M | $13M | $13M | $11M | $15M | $14M | |
| Current Liabilities | $42M | $53M | $18M | $21M | $20M | $26M | $22M | |
| Capital Leases | $15M | $15M | $15M | $15M | $15M | $15M | $15M | |
| Other Non-current Liabilities | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Total Liabilities | $59M | $73M | $36M | $39M | $38M | $44M | $41M | |
| Retained Earnings | $-693M | $-683M | $-667M | $-647M | $-616M | $-584M | $-555M | |
| AOCI | $-41.0K | $8.0K | $2.0K | $-1.0K | $12.0K | $35.0K | $167.0K | |
| Stockholders' Equity | $60M | $69M | $59M | $76M | $103M | $131M | $156M | |
| Liabilities + Equity | $120M | $141M | $95M | $115M | $141M | $176M | $197M |
Flux de trésorerie 10
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| D&A | $391.0K | $418.0K | $425.0K | $433.0K | $435.0K | $489.0K | $405.0K | |
| Stock-based Comp | $2M | $2M | $2M | $4M | $4M | $4M | $6M | |
| Restructuring | $0 | $851.0K | $0 | · | · | · | · | |
| Other Non-cash | $-14M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $-22M | $23M | $-19M | $-26M | $-34M | $-21M | $-27M | |
| CapEx | $0 | $0 | $0 | $20.0K | $47.0K | $53.0K | $63.0K | |
| Investing Cash Flow | $8M | $-60M | $40M | $12M | $62M | $22M | $11M | |
| Financing Cash Flow | $-314.0K | $25M | $-5.0K | $37.0K | $-160.0K | $-34.0K | $-131.0K | |
| Net Change in Cash | $-14M | $-12M | $21M | $-15M | $28M | $1M | $-17M | |
| Free Cash Flow | $-22M | · | · | · | $-34M | · | · |
Rentabilité 5
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -309.5% | · | -314.1% | · | · | · | -1145.9% | |
| Net Margin | -226.8% | · | -303.5% | · | · | · | -1075.7% | |
| EBITDA Margin | -301.0% | · | -314.1% | · | · | · | -1145.9% | |
| ROA | -8.0% | · | -13.5% | -18.4% | -16.5% | · | -14.2% | |
| ROE | -12.7% | · | -18.4% | -24.2% | -20.4% | · | -16.4% |
Liquidité et Solvabilité 2
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | · | 3.2 | 3.7 | 5.2 | · | 7.0 | |
| Quick Ratio | 2.0 | · | 3.0 | 3.5 | 5.0 | · | 6.9 |
Efficacité 1
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | 0.0 | · | · | · | 0.0 |
Valorisation (TTM) 3
| Métrique | Tendance | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-93M | · | $-115M | $-130M | $-131M | · | $-129M | |
| P/E | -2.8 | · | -0.9 | -0.5 | -0.4 | · | -1.2 | |
| Earnings Yield | -35.7% | · | -105.6% | -212.6% | -225.3% | · | -85.0% |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $12M | $7M | — | — | — |
| Marge d'exploitation % | -861.3% | -1995.9% | — | — | — |
| Résultat net | $-99M | $-127M | $-122M | $-115M | $-112M |
| BPA dilué | $-1.29 | $-1.68 | $-2.02 | $-2.44 | $-2.43 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio de liquidité | 2.0 | 5.3 | 10.8 | 9.4 | 15.4 |
| Ratio de liquidité réduite | 1.9 | 5.2 | 10.7 | 9.3 | 15.2 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-56M | $-104M | $-111M | $-87M | $-86M |
Dernières actualités Actualités récentes mentionnant cette entreprise
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.